The CROSS trial: End of the debate on neoadjuvant therapy for esophageal cancer?
Publication
, Journal Article
Pepek, JM; Willett, CG; Czito, BG
Published in: Clinical Practice
November 1, 2012
Duke Scholars
Published In
Clinical Practice
DOI
EISSN
2044-9046
ISSN
2044-9038
Publication Date
November 1, 2012
Volume
9
Issue
6
Start / End Page
607 / 609
Citation
APA
Chicago
ICMJE
MLA
NLM
Pepek, J. M., Willett, C. G., & Czito, B. G. (2012). The CROSS trial: End of the debate on neoadjuvant therapy for esophageal cancer? Clinical Practice, 9(6), 607–609. https://doi.org/10.2217/cpr.12.68
Pepek, J. M., C. G. Willett, and B. G. Czito. “The CROSS trial: End of the debate on neoadjuvant therapy for esophageal cancer?” Clinical Practice 9, no. 6 (November 1, 2012): 607–9. https://doi.org/10.2217/cpr.12.68.
Pepek JM, Willett CG, Czito BG. The CROSS trial: End of the debate on neoadjuvant therapy for esophageal cancer? Clinical Practice. 2012 Nov 1;9(6):607–9.
Pepek, J. M., et al. “The CROSS trial: End of the debate on neoadjuvant therapy for esophageal cancer?” Clinical Practice, vol. 9, no. 6, Nov. 2012, pp. 607–09. Scopus, doi:10.2217/cpr.12.68.
Pepek JM, Willett CG, Czito BG. The CROSS trial: End of the debate on neoadjuvant therapy for esophageal cancer? Clinical Practice. 2012 Nov 1;9(6):607–609.
Published In
Clinical Practice
DOI
EISSN
2044-9046
ISSN
2044-9038
Publication Date
November 1, 2012
Volume
9
Issue
6
Start / End Page
607 / 609